TCD Pharma Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

TCD Pharma General Information

Description

Developer of a drug development center designed to develop innovative therapies that address unmet medical needs. The company's center helps in treating cancer by providing an enzyme to regulate the production of phosphatidylcholine, a critical structural component required for the formation of the cell's membrane and cell proliferation, enabling patients to avail cure of Oncology at a reasonable rate.

Contact Information

Website
www.tcdpharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 4 José Antonio
  • Primo de Rivera Street
  • 47001 Valladolid
  • Spain
+34 983
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4 José Antonio
  • Primo de Rivera Street
  • 47001 Valladolid
  • Spain
+34 983

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TCD Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Mar-2018 Completed Out of Business
4. Grant 01-Oct-2016 Completed Generating Revenue
3. Early Stage VC (Series B) 10-Jan-2012 Completed Generating Revenue
2. Early Stage VC (Series A) 10-Mar-2010 $8.17M $11.2M Completed Startup
1. Early Stage VC 01-Jul-2005 $3.04M $3.04M Completed Startup
To view TCD Pharma’s complete valuation and funding history, request access »

TCD Pharma Patents

  • 36

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

TCD Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150087539-A1 Method for predicting outcome of cancer in a subject Inactive 19-Aug-2011
EP-2732049-A1 Method for predicting outcome of cancer in a subject Inactive 14-Jul-2011
US-20150004252-A1 Method for predicting the clinical response to chemotherapy in a subject with cancer Inactive 14-Jul-2011
JP-2014527397-A Methods for predicting clinical response to chemotherapy in cancer patients Pending 20-Jun-2011
EP-2721174-A1 Method for predicting the clinical response to chemotherapy in a subject with cancer Inactive 20-Jun-2011 C12Q1/6886
To view TCD Pharma’s complete patent history, request access »

TCD Pharma Investments (1)

TCD Pharma’s most recent deal was a Seed Round with Amadix for . The deal was made on 16-Nov-2011.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amadix 16-Nov-2011 Seed Round Diagnostic Equipment
To view TCD Pharma’s complete investments history, request access »

Ready to get started?

Request a free trial

TCD Pharma FAQs

  • When was TCD Pharma founded?

    TCD Pharma was founded in 2005.

  • Where is TCD Pharma headquartered?

    TCD Pharma is headquartered in Valladolid, Spain.

  • What industry is TCD Pharma in?

    TCD Pharma’s primary industry is Drug Discovery.

  • Is TCD Pharma a private or public company?

    TCD Pharma is a Private company.

  • What is TCD Pharma’s current revenue?

    The current revenue for TCD Pharma is .

  • How much funding has TCD Pharma raised over time?

    TCD Pharma has raised $13.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »